ArticleBMC cancer2023
Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany.
Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Therapeutic inhibition of myeloperoxidase with AZD5904 attenuates disease progression in mouse models of early stage and relapsed multiple myeloma.Haematologica · 2026Article
- Targeting Ikaros and Aiolos: Next-Generation Cereblon E3 Ligase Modulators in MM.European journal of haematology · 2026Review
- Role of Radiotherapy in the Era of Novel Immune-Based Treatment Strategies for Multiple Myeloma.Hematological oncology · 2026Review
- Elranatamab Versus Teclistamab in Relapsed and Refractory Multiple Myeloma: A Real-World Propensity Score-Matched Study.Targeted oncology · 2026Article
- Other primary malignancies are associated with inferior survival in multiple myeloma: a single-center matched retrospective cohort study.Frontiers in oncology · 2026Article
- Temporal trends and disparities in cardiovascular disease-related mortality among adults with multiple myeloma in the United States, 1999-2023.BMC cardiovascular disorders · 2025Article
- Prospective systematic classification of causes of death in the course of multiple myeloma.Blood cancer journal · 2025Article
- Transcriptional analysis of BMP2 and BMP6 in patients with newly diagnosed multiple myeloma.Oncology letters · 2025Article
- Determinants of 15-Year Progression-Free Survival in Multiple Myeloma; Real-World Data From a Single Institution.American journal of hematology · 2025Article
- Temporal patterns in US population-based patient survival among adults treated with chemotherapy and/or immunotherapy for multiple myeloma, 2000-2020.British journal of haematology · 2025Article
- Approaches To Managing Relapsed Myeloma: Switching Drug Class or Retreatment With Same Drug Class?Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025Review
- EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma.Future oncology (London, England) · 2025Article
- A real-world study on the impact of infection load on mortality in multiple myeloma patients in Finland.Annals of hematology · 2025Article
- Comparison of outcomes by race among a population-based matched sample of multiple myeloma patients.Cancer causes & control : CCC · 2025Article
- Health care systems as determinants of outcomes in multiple myeloma: final results from the Latin American MYLACRE study.Blood advances · 2025Observational
- A systematic review of direct oral anticoagulants for thromboprophylaxis in multiple myeloma.Research and practice in thrombosis and haemostasis · 2025Review
- Article
- Analysis of risk factors for major adverse cardiac events in patients with multiple myeloma.Frontiers in cardiovascular medicine · 2025Article
- Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study.Blood cancer journal · 2024Article
- The Perspective of Romanian Patients on Continuous Therapy for Multiple Myeloma.Journal of personalized medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSteady evolution of therapies has improved prognosis of patients with multiple myeloma (MM) over the past two decades. Yet, knowledge about survival trends and causes of death in MM might play a crucial role in long-term management of this patient collective. Here, we investigate time trends in myeloma-specific survival at the population level over two decades and analyse causes of death in times of prolonged survival.
methodsAge-standardised and age group-specific relative survival (RS) of MM patients aged < 80 years at diagnosis was estimated for consecutive time periods from 2000-2019 using data from the Cancer Registry of North Rhine-Westphalia in Germany. Conditional RS was estimated for patients who already survived one to five years post diagnosis. Causes of death in MM patients were analysed and compared to the general population using standardised mortality ratios (SMR).
resultsThree thousand three hundred thirty-six MM cases were included in the time trend analysis. Over two decades, age-standardised 5-year RS increased from 37 to 62%. Age-specific survival improved from 41% in period 2000-2004 to 69% in period 2015-2019 in the age group 15-69 years, and from 23 to 47% in the age group 70-79 years. Conditional 5-year RS of patients who survived five years after diagnosis slightly improved as compared to unconditional 5-year RS at diagnosis. MM patients are two times more likely to die from non-myeloma malignancies (SMR = 1.97, 95% CI 1.81-2.15) and from cardiovascular diseases (SMR = 2.01, 95% CI 1.86-2.18) than the general population.
conclusionsPrognosis of patients with MM has markedly improved since the year 2000 due to therapeutic advances. Nevertheless, late mortality remains a major concern. As survival improves, second primary malignancies and cardiovascular events deserve increased attention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.